PHILADELPHIA, May 13, 2008 (PRIME NEWSWIRE) -- Hemispherx Biopharma, Inc. (AMEX:HEB) announced its financial results for the fiscal quarter ended March 31, 2008. The net loss for this period was approximately $3,165,000 or ($0.04) per share compared to a loss of $5,100,000 or ($0.07) per share for the same period in 2007. This decrease in loss of $1,935,000 was primarily due to lower R&D costs and a reduction in financing costs and interest expense. The R&D costs in 2007 included $1,380,000 in increased Ampligen(r) production costs. Ampligen(r) is an experimental therapeutic with multiple potential applications. Financing costs and interest expense were also lower by $209,000 in 2008 reflecting the effect of paying down all our convertible debentures in June 2007.
